Brand Name
Vafseo
Generic Name
Vadadustat
View Brand Information FDA approval date: March 28, 2024
Classification: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
Form: Tablet
What is Vafseo (Vadadustat)?
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis [see Warnings and Precautions.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment